Filing Details
- Accession Number:
- 0001209191-23-032305
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-25 19:23:40
- Reporting Period:
- 2023-05-23
- Accepted Time:
- 2023-05-25 19:23:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1496323 | Igm Biosciences Inc. | IGMS | Pharmaceutical Preparations (2834) | 770349194 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1787359 | Misbah Tahir | C/O Igm Biosciences, Inc. 325 E Middlefield Road Mountain View CA 94043 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-15 | 398 | $11.71 | 51,970 | No | 5 | A | Direct | |
| Common Stock | Disposition | 2023-05-23 | 1,244 | $12.30 | 50,726 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-05-23 | 15 | $13.01 | 50,711 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
- This transaction was executed in multiple trades at prices ranging from $12.00 to $12.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $13.00 to $13.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Billionaire Hedge Funds
